Clinical research is an essential work to improve the treatment of oncological patients. This work is fruitless if it is carried out without cooperation projects between several hospitals. The cooperative effort is especially important in handling sarcomas, not only because of their rarity, but also due to their biological heterogeneity and the variability of their clinical behavior.
Phase II Trial of high doses of Ifosfamide as first line treatment on advanced soft tissue sarcomas.
Phase II Clinical trial of Adriamycin as second line treatment after hig dose Ifosfamide (Ensayo GEIS-01) on adult patients with advanced soft tissue sarcomas.
GEIS-02 (junio 1997)
Phase II Clinical trial of high doses of Ifosfamide plus Doxorubicin as first line treatment in advanced soft tissue sarcomas on adult patients.
GEIS-03 (diciembre 1997)
Pilot clinical trial phase II, open, prospective, without a control group and multicentric on the use of Liposomal Doxorubicin (Caelyxâ) as treatment of advanced soft tissue sarcomas pretreated with chemotherapy.
GEIS-04 (febrero 1999)
Phase II Trial, on high doses of Doxorubicin followed by high doses of Ifosfamide as first line treatment on advanced soft tissue sarcomas in adult patients.
Phase II Trial of Temozolomide as treatment for soft tissues sarcomas and gastrointestinal leiomyosarcomas.
Phase I-II trial with Gemcitabine on extended infusion and Adriamycin as first line treatment on advanced soft tissue sarcomas on adult patients.
Phase II Trial of Temozolomide with an orally administered scheme as first line for treatment of gynaecological sarcomas.
International prospective controlled randomized phase III clinical trial on high risk soft tissue sarcomas of limbs and thoracic lining on limited stage: integral approach including three to five chemotherapy cycles.(ISG Protocol: May 2002).
Randomized clinical trial on phase IV/III, prospective and multicentric comparing Adriamycin in standard doses versus sequential treatment with high Adriamycin doses followed by high doses of Ifosfamide, as first line treatment on advanced soft tissue sarcomas on adult patients.
International randomized controlled clinical trial on localized intermediate and high risk Gastrointestinal Stromal Tumors (GIST), completely extirpated with the presence of the KIT receptor, comparing adjuvant treatment with imatinib mesylate (Glivec) with no treatment after full surgery. (EORTC Protocol number 62024).
Comparative clinical trial phase II between DTIC and a combination of Gemcitabine and DTIC on soft tissue sarcomas on adult patients.
Clinical trial on phase I-II with Imatinib Mesylate and low doses of Adriamycin on patients with Gastrointestinal Stromal Tumor (GIST) refractory to Imatinib Mesylate.
Multicentric prospective, open, uncontrolled clinical trial, patients with ages equal or higher to 65 years old for the evaluation of the efficacy and safety of liposomal doxorubicin as first line treatment of soft tissue sarcomas.
Phase II multicentric non randomized Clinical trial, to evaluate the safety and efficacy of a combination of Sorafenib (bay 43-9006) and Ifosfamide as treatment of soft tissue sarcoma patients.
Phase II Clinical trial of neoadjuvant treatment with high doses of ifosfamide and concomitant radiotherapy on soft tissue sarcomas and identification of response-predictor markers.
Retrospective cohort analysis to evaluate the role of salvage surgery in imatinib sensitive gastrointestinal stromal tumor (GIST) patients with a good prognosit criteria.
Selective analysis of apoptosis markers on metastatic soft tissue sarcomas.
Retrospective molecular study of the therapeutic goals of Imatinib on endometrial stromal sarcomas: Protein and molecular expression of PDGFR or c-kit.
Role of Insulin Growth Factor receptor on the inherent and acquired resistance to imatinib on GIST patients.
Randomized phase II trial, open, multicentric and prospective of doxorubicin vs trabectedin and doxorubicin as first line treatment of unoperable and metastatic soft tissue sarcoma patients.
Phase III Clinical trial, to evaluate surgery of residual disease in patients with Gastrointestinal Stromal Tumor with response to imatinib mesylate
Soft tissue sarcoma registry as a tool for the evaluation of the compliance to clinical practice guidelines defined by GEIS
Phase I/II randomized, prospective, multicentric Clinical trial, with the combination of gemcitabine and rapamycin (sirolimus) versus only gemcitabine in advanced soft tissue sarcomas.
Phase I/II prospective multicentric Trial of nilotinib and adriamycin as neoadjuvant treatment of retroperitoneal liposarcomas and leiomyosarcomas
Phase II Clinical trial of cedinarib for the treatment of alveolar soft tissue sarcoma patients (CASPS)
Phase II Clinical Trial of Pazopanib to evaluate the activity and tolerability in patients with advanced and/or metastatic liposarcoma who have relapsed following standard therapies or for whom no standard therapy exists.
Phase I-II trial of sunitinib plus nivolumab after standard treatment in advanced soft tissue and bone sarcomas.